HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Access to pain management hampered by addiction fears, government regulations
-
- Vaccine prolonged time to relapse in patients with follicular lymphoma
- Success of imatinib in man with CML-CP wanting to have children Sheetal Shrimanker, MD
- Unraveling mucous could be TTP therapeutic breakthrough Harry S. Jacob, MD, DHC
- Combined 18F/18F FDG PET/CT scan shows potential for use in cancer detection
- Elderly female presents with asymptomatic leukocytosis Munir Ghesani, MD, FACNM; Amit Patel, MD; Rami Daya, MD
- Nearly half of stem cell transplant survivors had reduced neurocognitive function after 5 years
- Time to treatment predictive for survival in colorectal cancer
- AXIS 1032: Axitinib associated with extended PFS in metastatic RCC
-
- Bevacizumab improved pathological, clinical response rates in metastatic breast cancer
- CA-125, transvaginal ultrasound for early detection did not reduce ovarian cancer mortality
- CLASSIC: Capecitabine, oxaliplatin bested observation in gastric cancer
- COMFORT: Ruxolitinib improved response rates in myelofibrosis
- Early palliative care optimized timing of final IV chemotherapy, transition to hospice
- FACT: Addition of CA4P in combination therapy improved OS in anaplastic thyroid cancer
- ICON7: Bevacizumab reduced deaths by 36% in advanced ovarian cancer
- Ipilimumab plus dacarbazine improved survival in metastatic melanoma
-
- MAP.3: Exemestane reduced risk for breast cancer by 65%
- Pemetrexed maintenance therapy prolonged PFS in advanced NSCLC
- Regional nodal irradiation reduced recurrence in high-risk early breast cancer
- Sunitinib, non-ritonavir-based HAART well-tolerated in patients with HIV
- Targeted therapy increased response rates, survival in patients with molecular abnormalities
- Three-year treatment with imatinib improves survival for high-risk GIST
- Vemurafenib improved OS, PFS in V600EBRAF mutated melanoma